141 related articles for article (PubMed ID: 26281860)
1. Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study.
Dodson A; Zabaglo L; Yeo B; Miller K; Smith I; Dowsett M
J Clin Pathol; 2016 Feb; 69(2):128-35. PubMed ID: 26281860
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
Cuzick J; Dowsett M; Pineda S; Wale C; Salter J; Quinn E; Zabaglo L; Mallon E; Green AR; Ellis IO; Howell A; Buzdar AU; Forbes JF
J Clin Oncol; 2011 Nov; 29(32):4273-8. PubMed ID: 21990413
[TBL] [Abstract][Full Text] [Related]
3. Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer.
Sheri A; Smith IE; Hills M; Jones RL; Johnston SR; Dowsett M
Breast Cancer Res Treat; 2017 Jul; 164(2):395-400. PubMed ID: 28447240
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer.
Barton S; Zabaglo L; A'Hern R; Turner N; Ferguson T; O'Neill S; Hills M; Smith I; Dowsett M
Br J Cancer; 2012 May; 106(11):1760-5. PubMed ID: 22531639
[TBL] [Abstract][Full Text] [Related]
5. IHC4 score plus clinical treatment score predicts locoregional recurrence in early breast cancer.
Lakhanpal R; Sestak I; Shadbolt B; Bennett GM; Brown M; Phillips T; Zhang Y; Bullman A; Rezo A
Breast; 2016 Oct; 29():147-52. PubMed ID: 27498128
[TBL] [Abstract][Full Text] [Related]
6. Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer.
Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Fu P; Honda Y; Iyama K; Iwase H
Mod Pathol; 2013 Jan; 26(1):79-86. PubMed ID: 22918168
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
8. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
9. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
[TBL] [Abstract][Full Text] [Related]
10. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
[TBL] [Abstract][Full Text] [Related]
11. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
Cortesi L; De Matteis E; Cirilli C; Marcheselli L; Proietto M; Federico M
Tumori; 2012 Nov; 98(6):743-50. PubMed ID: 23389361
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
[TBL] [Abstract][Full Text] [Related]
13. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
[TBL] [Abstract][Full Text] [Related]
14. Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment.
Ekholm M; Grabau D; Bendahl PO; Bergh J; Elmberger G; Olsson H; Russo L; Viale G; Fernö M
Acta Oncol; 2015 Jul; 54(7):1040-8. PubMed ID: 25959664
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.
Rohan TE; Xue X; Lin HM; D'Alfonso TM; Ginter PS; Oktay MH; Robinson BD; Ginsberg M; Gertler FB; Glass AG; Sparano JA; Condeelis JS; Jones JG
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 24895374
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
17. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
Rexhepaj E; Jirstrom K; O'Connor DP; O'Brien SL; Landberg G; Duffy MJ; Brennan DJ; Gallagher WM
BMC Cancer; 2010 Nov; 10():639. PubMed ID: 21092276
[TBL] [Abstract][Full Text] [Related]
18. Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer.
Abubakar M; Figueroa J; Ali HR; Blows F; Lissowska J; Caldas C; Easton DF; Sherman ME; Garcia-Closas M; Dowsett M; Pharoah PD
Mod Pathol; 2019 Sep; 32(9):1244-1256. PubMed ID: 30976105
[TBL] [Abstract][Full Text] [Related]
19. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
20. A National Quality Assurance program for breast immunohistochemistry: an Italian perspective.
Guadagno E; De Rosa G; Nappi O
Pathologica; 2018 Sep; 110(2):83-91. PubMed ID: 30546143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
